All Years | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
2024 — 18 Books and Research Papers Citing DrugPatentWatch
Davolos, F. J. C., Modolo, N. S., Braz, L. G., & do Nascimento Junior, P. (2024). Palonosetron versus ondansetron for prophylaxis of postoperative nausea and vomiting in laparoscopic cholecystectomy: A non-inferiority randomized controlled trial. Brazilian Journal of Anesthesiology, 74(1), e744216.
This randomized controlled trial compares the efficacy of palonosetron and ondansetron in preventing postoperative nausea and vomiting during laparoscopic cholecystectomy. The study found that palonosetron was non-inferior to ondansetron, suggesting its potential as an alternative antiemetic. The authors utilized DrugPatentWatch to analyze the patent landscape of both drugs, highlighting the implications for generic entry and market competition.
Reza, A. A. (2024). Evaluation of the online pharmaceutical market and the dangers of counterfeit medicines: Comprehensive investigation of illicit online trade of semaglutide. pea.lib.pte.hu.
This investigation delves into the illicit online trade of semaglutide, focusing on counterfeit products. The study emphasizes the risks associated with purchasing medications from unverified online sources. DrugPatentWatch was cited for providing insights into the patent status and market exclusivity of semaglutide, underscoring the importance of patent protection in combating counterfeit drugs.
Niazi, S. K. (2024). Advice to the US FDA to allow US Pharmacopeia to create biological product specifications (BPS) to remove side-by-side analytical comparisons of biosimilars. Pharmaceutics.
Niazi advocates for the US FDA to permit the US Pharmacopeia to establish Biological Product Specifications (BPS) to eliminate the need for side-by-side analytical comparisons of biosimilars. The paper discusses the implications for patent law and market exclusivity. DrugPatentWatch was referenced for its database on patent expirations and exclusivity periods, providing context for the discussion on biosimilar market entry.
Swain, A., & Rout, P. C. (2024). A study on authorized generics and branded generics: A perspective analysis among the pharmacy students in India. ANWESHAN.
This study explores the perceptions of pharmacy students in India regarding authorized and branded generics. It highlights the differences in market dynamics, pricing, and consumer trust between the two categories. DrugPatentWatch was cited for providing data on patent expirations and generic entry dates, which are crucial for understanding the generics market.
Zahur, N. B., & Wang, L. X. (2024). Procurement institutions and essential drug supply in low and middle-income countries. econstor.eu.
This paper examines the role of procurement institutions in ensuring the supply of essential drugs in low and middle-income countries. It discusses challenges such as patent barriers and high drug prices. DrugPatentWatch was referenced for its insights into patent expirations and generic entry opportunities, which are vital for improving drug accessibility in these regions.
Eapen, A. T. (2024). The science of supply: Applying diffusion models to predict and prevent drug shortages. search.proquest.com.
Eapen applies diffusion models to predict and prevent drug shortages, focusing on supply chain dynamics and market factors. The study emphasizes the importance of understanding patent expirations and market exclusivity periods. DrugPatentWatch was cited for providing data on patent expirations and generic entry dates, which are essential for forecasting drug supply issues.
Olatoye, F. S. (2024). Global sustainability and sustainable competitive advantage in business (Case study-Teva Pharmaceutical Inc. Strategy review between 1976-2020). ResearchGate.
Olatoye reviews Teva Pharmaceutical Inc.'s strategies over four decades, focusing on sustainability and competitive advantage. The paper discusses Teva's approach to patenting and generic drug production. DrugPatentWatch was cited for its comprehensive database on drug patents and market exclusivity, providing context for Teva's strategic decisions.
Nam, K. Y., & Park, J. I. (2024). Legal research on improving the pharmaceutical patent term extension system for entering an aging society. The Journal of Intellectual Property.
Nam and Park explore the pharmaceutical patent term extension system, proposing improvements to address the challenges posed by an aging society. The paper discusses the balance between incentivizing innovation and ensuring drug accessibility. DrugPatentWatch was cited for its data on patent expirations and exclusivity periods, informing the discussion on patent term extensions.
Ledley, F. D., & Zhou, E. (2024). Comments re: Draft guidance considering exercise of march-in rights-Docket No.: 230831-0207. scholars.bentley.edu.
Ledley and Zhou provide comments on the draft guidance regarding the exercise of march-in rights, focusing on the implications for patent law and public health. The paper discusses the conditions under which march-in rights may be exercised to ensure drug accessibility. DrugPatentWatch was referenced for its insights into patent expirations and market exclusivity, which are central to the discussion on march-in rights.
Handbook of Biological Therapeutic Proteins: Regulatory, Manufacturing, Testing, and Patent Issues
S Niazi - 2024 - books.google.com
Considering Returns on Federal Investment in the Negotiated “Maximum Fair Price” of Drugs Under the Inflation Reduction Act: an Analysis
EW Zhou, PG Chaves da Silva, D Quijada… - Institute for New …, 2024 - papers.ssrn.com
Sandhu, A. D. (2024). Skinny labels: Changing scenario of induced infringement and public policy. Santa Clara High Technology Law Journal.
Sandhu examines the evolving landscape of induced patent infringement, particularly in the context of 'skinny labels' for generic drugs. The paper analyzes how public policy is adapting to these changes. DrugPatentWatch was cited for its data on patent expirations and exclusivity periods, providing a foundation for understanding the implications of skinny labels.
Niazi, S. K. (2024). Biosimilars development strategies: Fast to market approaches. books.google.com.
Niazi discusses strategies for the rapid development and market entry of biosimilars, focusing on regulatory pathways and patent considerations. The paper emphasizes the importance of understanding patent landscapes to navigate the complexities of biosimilar development. DrugPatentWatch was referenced for its comprehensive database on drug patents and market exclusivity, aiding in strategic planning for biosimilar development.
Vasilishina, Y. (2024). Driver for innovation. innosfera.belnauka.by.
Vasilishina explores the drivers of innovation in the pharmaceutical industry, focusing on patenting and intellectual property strategies. The paper discusses how patent protections influence research and development priorities. DrugPatentWatch was cited for its insights into patent expirations and market exclusivity periods, highlighting their impact on innovation trajectories.
고령화 사회 진입을 향한 제약특허 존속기간 연장제도 개선에 관한 법적 연구
남기연， 박정인 - 지식재산연구, 2024 - dbpia.co.kr
Kirova, D. (2024). Organization of operational management of production at the enterprise-subject of foreign economic activity (on the example of AT Farmak). dspace.znu.edu.ua.
Kirova examines the operational management of production at AT Farmak, focusing on foreign economic activities. The study discusses challenges related to patenting and market access. DrugPatentWatch was referenced for its data on patent expirations and generic entry opportunities, providing context for the analysis of operational strategies.
Mazur, I. S. (2024). Study of the peculiarities of foreign economic activity of AT Farmak. evnuir.vnu.edu.ua.
Mazur investigates the peculiarities of foreign economic activity at AT Farmak, focusing on international trade and patent considerations. The paper discusses how patent laws influence global market strategies. DrugPatentWatch was cited for its insights into patent expirations and market exclusivity, informing the study's analysis.
Ivanova, E. S. (2023). Ways and methods of ensuring the competitiveness of pharmaceutical products of AT Farmak in the foreign market. dspace.znu.edu.ua.
Ivanova explores strategies to ensure the competitiveness of AT Farmak products in foreign markets, focusing on patenting and intellectual property management. The study discusses how patent protections can enhance or hinder competitiveness. DrugPatentWatch was referenced for its data on patent expirations and market exclusivity periods, providing a foundation for the analysis.
